Relationship between Antithrombin III Activity and Mortality in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

References

• López-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14–23. Epub 2015/10/24. DOI:10.1111/resp.12660
   PubMed Web of Science ®Google Scholar
• Løkke A, Hilberg O, Tønnesen P, et al. Direct and indirect economic and health consequences of COPD in Denmark: a national register-based study: 1998–2010. BMJ Open. 2014;2014/;4(1):e004069. Epub 01/08. DOI:10.1136/bmjopen-2013-004069 PubMed PMID: 24394800; PubMed Central PMCID: PMCPMC3902350.
   PubMed Web of Science ®Google Scholar
• Liu M, Hu R, Jiang X, et al. Coagulation dysfunction in patients with AECOPD and its relation to infection and hypercapnia. J Clin Lab Anal. 2021;35(4):e23733. Epub 2021/03/26. DOI:10.1002/jcla.23733 PubMed PMID: 33764623; PubMed Central PMCID: PMCPMC8059715.
   PubMed Web of Science ®Google Scholar
• DAHL M, TYBJOERG-HANSEN ANNE, VESTBO J, et al. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(6):1008–1011. Epub 2001/10/06. doi:10.1164/ajrccm.164.6.2010067.
   PubMed Web of Science ®Google Scholar
• Duvoix A, Dickens J, Haq I, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax. 2013;68(7):670–676. Epub 2012/06/30. DOI:10.1136/thoraxjnl-2012-201871 PubMed PMID: 22744884; PubMed Central PMCID: PMCPMC3711372.
   PubMed Web of Science ®Google Scholar
• Serban KA, Pratte KA, Bowler RP. Protein biomarkers for COPD outcomes. Chest. 2021;159(6):2244–2253. Epub 2021/01/13. DOI:10.1016/j.chest.2021.01.004 PubMed PMID: 33434499; PubMed Central PMCID: PMCPMC8213963.
   PubMed Web of Science ®Google Scholar
• Husebø GR, Gabazza EC, D’Alessandro Gabazza C, et al. Coagulation markers as predictors for clinical events in COPD. Respirology. 2021;26(4):342–351. Epub 2020/11/10. DOI:10.1111/resp.13971
   PubMed Web of Science ®Google Scholar
• Fruchter O, Yigla M, Kramer MR. D-dimer as a prognostic biomarker for mortality in chronic obstructive pulmonary disease exacerbation. Am J Med Sci. 2015;349(1):29–35. Epub 2014/09/19. DOI:10.1097/maj.0000000000000332
   PubMed Web of Science ®Google Scholar
• Vaidyula VR, Criner GJ, Grabianowski C, et al. Circulating tissue factor procoagulant activity is elevated in stable moderate to severe chronic obstructive pulmonary disease. Thrombosis Research. 2009;124(3):259–261. Epub 2009/01/24. PubMed PMID: 19162305; PubMed Central PMCID: PMCPMC2877030. DOI:10.1016/j.thromres.2008.12.030
   PubMed Web of Science ®Google Scholar
• Kunter E, Ilvan A, Ozmen N, et al. Effect of corticosteroids on hemostasis and pulmonary arterial pressure during chronic obstructive pulmonary disease exacerbation. Respiration. 2008;75(2):145–154. Epub 2006/12/05. DOI:10.1159/000097748
   PubMed Web of Science ®Google Scholar
• Mariĭnov K, Petrova D, Kamenov V, et al. Anticoagulants and changes in the coagulation status of patients with chronic obstructive lung disease and various degrees of respiratory failure. Vutreshni Bolesti. 1988;27(1):86–93. Epub 1988/01/01.
   PubMedGoogle Scholar
• Zuo XJ, Nicolaidou E, Okada Y, et al. Antithrombin III inhibits lymphocyte proliferation, immunoglobulin production and mRNA expression of lymphocyte growth factors (IL-2, gamma-IFN and IL-4) in vitro. Transpl Immunol. 2001;9(1):1–6. Epub 2001/10/30. DOI:10.1016/s0966-3274(01)00042-9
   PubMed Web of Science ®Google Scholar
• Umerah CO, Momodu II. Anticoagulation. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC; 2022.
   Google Scholar
• Di Stefano A, Turato G, Maestrelli P, et al. Airflow limitation in chronic bronchitis is associated with T-lymphocyte and macrophage infiltration of the bronchial mucosa. Am J Respir Crit Care Med. 1996;153(2):629–632. Epub 1996/02/01. DOI:10.1164/ajrccm.153.2.8564109
   PubMed Web of Science ®Google Scholar
• Ma Y, Wang J, Gao J, et al. Antithrombin up-regulates AMP-activated protein kinase signalling during myocardial ischaemia/reperfusion injury. Thromb Haemost. 2015;113(2):338–349. Epub 2014/09/19. DOI:10.1160/th14-04-0360 PubMed PMID: 25230600; PubMed Central PMCID: PMCPMC4308562.
   PubMed Web of Science ®Google Scholar
• Aytekin FO, Tekin K, Kabay B, et al. Antithrombin III attenuates pulmonary tissue injury caused by mesenteric ischemia-reperfusion. Am J Surg. 2005;189(2):161–166. Epub 2005/02/22. DOI:10.1016/j.amjsurg.2004.11.003
   PubMed Web of Science ®Google Scholar
• Lu J, Niu D, Zheng D, et al. Predictive value of combining the level of lipoprotein-associated phospholipase A2 and antithrombin III for acute coronary syndrome risk. Biom Rep. 2018;9(6):517–522. Epub 2018/12/14. PubMed PMID: 30546880; PubMed Central PMCID: PMCPMC6256189. DOI:10.3892/br.2018.1162
   PubMed Web of Science ®Google Scholar
• Lestari IN, Yoel C, Lubis M. The association between the level of antithrombin III and mortality in children with sepsis. Open Access Maced J Med Sci. 2019;7(6):959–961. Epub 2019/04/13. DOI:10.3889/oamjms.2019.211 PubMed PMID: 30976340; PubMed Central PMCID: PMCPMC6454173.
   PubMedGoogle Scholar
• Pettilä V, Pentti J, Pettilä M, et al. Predictive value of antithrombin III and serum C-reactive protein concentration in critically ill patients with suspected sepsis. Crit Care Med. 2002;30(2):271–275. Epub 2002/03/13. DOI:10.1097/00003246-200202000-00001
   PubMed Web of Science ®Google Scholar
• Allingstrup M, Wetterslev J, Ravn FB, et al. Antithrombin III for critically ill patients. Cochrane Database Syst Rev. 2016;2(2):Cd005370. // DOI:10.1002/14651858.CD005370.pub3
   PubMedGoogle Scholar
• StatBox: A Online Statistical Computing System. Biostatistics Team of CMT. https://www.biostats.cn/statbox/.
   Google Scholar
• GOLD Executive Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (Updated 2017). Available from: https://goldcopd.org/.
   Google Scholar
• Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–35. Epub 1950/01/01. DOI:10.1002/1097-0142(1950)3:1 < 32::aid-cncr2820030106 > 3.0.co;2-3
   PubMed Web of Science ®Google Scholar
• Wirtz HR. [Chronic bronchitis, COPD]. Internist (Berl). 2005;46(2):175–191. quiz 92-3. Epub 2005/01/19. DOI:10.1007/s00108-004-1335-z
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu J, Meng Y, et al. Role of inflammatory cells in airway remodeling in COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:3341–3348. Epub 2018/10/24. DOI:10.2147/copd.S176122 PubMed PMID: 30349237; PubMed Central PMCID: PMCPMC6190811.
   PubMed Web of Science ®Google Scholar
• Polosa R, Malerba M, Cacciola RR, et al. Effect of acute exacerbations on circulating endothelial, clotting and fibrinolytic markers in COPD patients. Intern Emerg Med. 2013;8(7):567–574. Epub 2011/06/11. DOI:10.1007/s11739-011-0636-1
   PubMed Web of Science ®Google Scholar
• Sungurlu S, Kuppy J, Balk RA. Role of antithrombin III and tissue factor pathway in the pathogenesis of sepsis. Crit Care Clin. 2020;36(2):255–265. Epub 2020/03/17. DOI:10.1016/j.ccc.2019.12.002
   PubMed Web of Science ®Google Scholar
• Bergantini L, d’Alessandro M, Cameli P, et al. Antithrombin III as predictive indicator of survival in idiopathic pulmonary fibrosis (IPF) patients treated with nintedanib: a preliminary study. Intern Med J. 2021;51(5):705–711. Epub 2020/02/11. DOI:10.1111/imj.14768
   PubMed Web of Science ®Google Scholar
• Rehberg S, Yamamoto Y, Sousse LE, et al. Antithrombin attenuates vascular leakage via inhibiting neutrophil activation in acute lung injury. Crit Care Med. 2013;41(12):e439-46. Epub 2013/10/11. DOI:10.1097/CCM.0b013e318298ad3aPubMed PMID: 24107637; PubMed Central PMCID: PMCPMC4063122.
   PubMed Web of Science ®Google Scholar
• Zemans RL, Jacobson S, Keene J, et al. Multiple biomarkers predict disease severity, progression and mortality in COPD. Respir Res. 2017;18(1):117. Epub 2017/06/15. DOI:10.1186/s12931-017-0597-7 PubMed PMID: 28610627; PubMed Central PMCID: PMCPMC5470282.
   PubMed Web of Science ®Google Scholar
• Leuzzi G, Galeone C, Taverna F, et al. C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis. Eur Respir Rev. 2017;26(143):160070. Epub 2017/02/02. DOI:10.1183/16000617.0070-2016
   PubMed Web of Science ®Google Scholar
• Mannino DM, Tal-Singer R, Lomas DA, et al. Plasma fibrinogen as a biomarker for mortality and hospitalized exacerbations in people with COPD. Chron Obstr Pulm Dis. 2015;2(1):23–34. Epub 2015/02/17. DOI:10.15326/jcopdf.2.1.2014.0138 PubMed PMID: 25685850; PubMed Central PMCID: PMCPMC4326107.
   PubMed Web of Science ®Google Scholar
• Undas A, Jankowski M, Kaczmarek P, et al. Thrombin generation in chronic obstructive pulmonary disease: dependence on plasma factor composition. Thrombosis Res. 2011;128(4):e24-8–e28. Epub 2011/06/01. PubMed PMID: 21624643; PubMed Central PMCID: PMCPMC3183323. DOI:10.1016/j.thromres.2011.05.004
   PubMed Web of Science ®Google Scholar
• Hu G, Wu Y, Zhou Y, et al. Prognostic role of D-dimer for in-hospital and 1-year mortality in exacerbations of COPD. Int J Chron Obstructive Pulm Dis. 2016;11:2729–2736. Epub 2016/11/16. PubMed PMID: 27843309; PubMed Central PMCID: PMCPMC5098517. DOI:10.2147/COPD.S112882
   PubMed Web of Science ®Google Scholar
• Hartl S, Lopez-Campos JL, Pozo-Rodriguez F, et al. Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD audit. Eur Respir J. 2016;47(1):113–121. Epub 2015/10/24. DOI:10.1183/13993003.01391-2014
   PubMed Web of Science ®Google Scholar
• Morasert T, Jantarapootirat M, Phinyo P, et al. Prognostic indicators for in-hospital mortality in COPD with acute exacerbation in Thailand: a retrospective cohort study. BMJ Open Resp Res. 2020;7(1):e000488. Epub 2020/05/30. PubMed PMID: 32467292; PubMed Central PMCID: PMCPMC7259855. DOI:10.1136/bmjresp-2019-000488
   PubMed Web of Science ®Google Scholar
• Moll M, Qiao D, Regan EA, et al. Machine learning and prediction of all-cause mortality in COPD. Chest. 2020;158(3):952–964. Epub 2020/05/01. PubMed PMID: 32353417; PubMed Central PMCID: PMCPMC7478228. DOI:10.1016/j.chest.2020.02.079
   PubMed Web of Science ®Google Scholar
• Horodinschi RN, Bratu OG, Dediu GN, et al. Heart failure and chronic obstructive pulmonary disease: a review. Acta Cardiol. 2020;75(2):97–104. Epub 2019/01/17. DOI:10.1080/00015385.2018.1559485
   PubMed Web of Science ®Google Scholar
• Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962–969. Epub 2008/06/27. doi:10.1183/09031936.00012408.
   PubMed Web of Science ®Google Scholar
• Cavaillès A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. Eur Respir Rev. 2013;22(130):454–475. Epub 2013/12/03. DOI:10.1183/09059180.00008612
   PubMedGoogle Scholar
• Kostikas K, Clemens A, Patalano F. Prediction and prevention of exacerbations and mortality in patients with COPD. Expert Rev Respir Med. 2016;10(7):739–753. Epub 2016/05/03. DOI:10.1080/17476348.2016.1185371
   PubMed Web of Science ®Google Scholar
• Ashitani J, Mukae H, Arimura Y, et al. Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. Intern Med. 2002;41(3):181–185. Epub 2002/04/04. DOI:10.2169/internalmedicine.41.181
   PubMed Web of Science ®Google Scholar
• Di Minno MN, Dentali F, Lupoli R, et al. Mild antithrombin deficiency and risk of recurrent venous thromboembolism: a prospective cohort study. Circulation. 2014;129(4):497–503. Epub 2013/10/23. DOI:10.1161/circulationaha.113.003756
   PubMed Web of Science ®Google Scholar
• Sokol J, Timp JF, Cessie S, et al. Mild antithrombin deficiency and risk of recurrent venous thromboembolism: results from the MEGA follow-up study. J Thromb Haemost. 2018;16(4):680–688. Epub 2018/01/30. DOI:10.1111/jth.13960
   PubMed Web of Science ®Google Scholar
• Erelel M, Cuhadaroğlu C, Ece T, et al. The frequency of deep venous thrombosis and pulmonary embolus in acute exacerbation of chronic obstructive pulmonary disease. Respir Med. 2002;96(7):515–518. Epub 2002/08/27. DOI:10.1053/rmed.2002.1313
   PubMed Web of Science ®Google Scholar
• Aleva FE, Voets L, Simons SO, et al. Prevalence and localization of pulmonary embolism in unexplained acute exacerbations of COPD: a systematic review and Meta-analysis. Chest. 2017;151(3):544–554. Epub 2016/08/16. DOI:10.1016/j.chest.2016.07.034
   PubMed Web of Science ®Google Scholar